Sigyn TherapeuticsSIGY +22.62% Gross Margin % is 0.00% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Sigyn Therapeutics ranks worse than 136611.89% on this metric.
The historical rank and industry rank for Sigyn Therapeutics's Gross Margin % or its related term are showing as below:
During the past 11 years, the highestGross Margin % of Sigyn Therapeutics was 75.52%. The lowest was 44.74%. And the median was 62.00%.
SIGY's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Sigyn Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sigyn Therapeutics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sigyn Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sigyn Therapeutics Gross Margin % Related Terms
Sigyn Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sigyn Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SIGY vs RGBP, ENDV, VRTX: Gross Margin % Comparison
For the Biotechnology subindustry, Sigyn Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigyn Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sigyn Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sigyn Therapeutics (SIGY) has a Gross Margin % of 0.00% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sigyn Therapeutics and its competitors. Over the past decade, Sigyn Therapeutics' Gross Margin % has ranged from 44.74 to 75.52. According to the industry distribution chart, Sigyn Therapeutics ranks #999999 out of 732 companies in the Biotechnology industry.
Is Sigyn Therapeutics' Gross Margin % too high?
Sigyn Therapeutics' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 44.74 to a high of 75.52. Based on the distribution chart, Sigyn Therapeutics ranks #999999 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Sigyn Therapeutics' Gross Margin % compare to RGBP and ENDV?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #999999 out of 732 companies for Gross Margin %. This places Sigyn Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Sigyn Therapeutics' own Gross Margin % has ranged from 44.74 to 75.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sigyn Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigyn Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current Gross Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SIGY has been successfully added to your 